I do not agree with Page 25 "Re-rating ResApp Health". I think $0.85 will be achieved before FDA approval rather than AFTER first approval of FDA.
If the accuracy is above 80% from US hospital study, then many institutions will be interested and RAP can easily go over $0.85 by then.
NDF Research, page-11
Add RAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| RAP (ASX) Chart |
Day chart unavailable